CAS: 112-59-4; 2-(2-(Hexyloxy)Ethoxy)Ethanol

相似化合物

25961-89-1 3055-99-0 19327-39-0

上下游产品

CAS号111-25-1 1-溴代正己烷 | CAS号75-21-8 环氧乙烷 | CAS号111-27-3 正己醇 | CAS号111-46-6 二乙二醇 | CAS号112-25-4 乙二醇己醚 | CAS号25961-89-1 2-[2-(2-己氧基乙氧基)... | CAS号72510-64-6 1-[2-(2-chloroe...

溴己烷,二乙二醇置于potassium Hydroxide体系中,用 1,4-二氧六环 用作溶剂,以68%的收率获得二乙二醇单己醚
参考文献:在氮原子上含有ω-烷氧基乙基和2-羟乙基取代基的无环季铵化合物的合成
标题:在氮原子上含有ω-烷氧基乙基和2-羟乙基取代基的无环季铵化合物的合成
摘要:一系列无环对称季铵氯化物 Me2(Hoch2Ch2)N+(Ch2Ch2O)Nr Cl-(N = 1,R = N-C9H19; N = 2,R = N-C6H13; N = 3,R = N-C3H7)由相应的叔胺 Me2N(Ch2Ch2O)Nr 与亚乙基氯醇在两相系统中烷基化合成,使用水作用作溶剂.叔胺是在非均相系统有机相-水相中合成的,使用 Me2Nh 和固体碱的水溶液.通过在二恶烷中使用固体 Koh 进行相转移烷基化,以高收率获得了乙烯,二甘醇和三甘醇的中间体单醚.合成的胺和氯化铵的 NMR 光谱中的质子和碳原子信号是基于异核相关性 (1H,13C) 的数据分配的.
Doi:10.1007/s11172-015-1209-7

专利信息

专利号:US-2014342177-A1
优先权日:2011-12-07
标 题 :Synthesis of cupronickel nanowires and their application in transparent conducting films
发明人：WILEY BENJAMIN
权利人:UNIV DUKE
摘要:A method of synthesis to produce a conductive film including cupronickel nanowires. Cupronickel nanowires can be synthesized from solution, homogeneously dispersed and printed to make conductive films (preferably < 1,000 Ω/sq) that preferably transmit greater than 60% of visible light.

专利号:WO-8503665-A1
优先权日:1984-02-15
标题:Synthesis of polyurethane products
发明人：HOSTETTLER FRITZ
权利人:PIRRI JAQUELYN P; HOSTETTLER FRITZ
摘要:Wide range of polyurethane products, e.g., cellular, dense elastomer, and integral skin microcellular products, obtained by the reaction of (a) a polyisocyanate compound, (b) a polyol, (c) optionally a chain extender and/or blowing agent with/without other known additives, (d) in the presence of a nonhydroxyl flow modifier characterized by carbon and hydrogen atoms, at least one and, generally, a plurality of oxyalkylene groups, and at least one urethane, $(1,5)omicronp. Several of the polyurethane products exhibit unique properties, e.g., foamed articles with capability to conduct static electricity, soft elastomers characterized by improved coefficient of friction, etc. Several classes of the flow modifiers are novel per se. The polyurethane products can be synthesized via the one shot or prepolymer process. Multipackage systems, in particular, two and three component systems are useful in molding operations, e.g., manufacture of shoe soles.

专利号:US-5753726-A
优先权日:1995-12-20
标 题:Synthesis of modified epoxy resins for cathodic electrodeposition with catalyst deactivation and diol modification
发明人：REUTER HARDY; JOUCK WALTER; OTT GUENTHER
权利人:BASF LACKE & FARBEN
摘要:Epoxy resins for preparing water-dispersible binders for cathodic electrodeposition coating materials, the epoxy resin being preparable by reacting a) polyepoxides having at least one glycidyl group per molecule b) and, optionally, up to 60% by weight, based on the overall epoxy resin reaction product, of aliphatic and/or alicyclic hydroxy compounds having preferably two or on average less than two hydroxyl groups per molecule and a molecular weight of less than 9000 g/mol, c) in the presence of a catalyst consisting of neutral metal salts, such as alkali metal salts and alkaline earth metal salts, zinc salts and nickel salts of tetrafluoroboric, tetrachloroboric, hexafluoro- antimonic,hexachloroantimonic,hexafluorophosphoric, perchlorate and periodic acid, and d) adding a deactivating agent which prevents the epoxy groups reacting further or effectively reduces the rate of such reaction as soon as the phenolic hydroxyl groups have already substantially reacted and at least 0.6% by weight of epoxy groups are still present, based on the overall weight of the epoxy resin reaction product.\\!

专利号:US-2010184989-A1
优先权日:2007-03-12
标 题 :De Novo Synthesis of Conjugates
发明人：RIGGS-SAUTHIER JENNIFER; DENG BO-LIANG; REN ZHONGXU; ZHANG WEN; GU XUYUAN; DUARTE FRANCO J
权利人:NEKTAR THERAPEUTICS
摘要:The invention provides methods for the preparation of small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a water-soluble oligomer composition. Such drugs are produced through modification of a synthetic pathway to attach the oligomer to an intermediate compound followed by completion of the synthetic path.

专利号:US-6695969-B1
优先权日:1998-09-18
标 题 :Process for obtaining HMG-CoA reductase inhibitors of high purity
发明人：GRAHEK ROK; MILIVOJEVIC DUSAN; BASTARDA ANDREJ
权利人:LEK PHARMACEUTICALS
摘要:Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as and antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergilus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicilium genus, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-CoA reductase inhibitors using so-called displacement chromatography. Use of the invention enables to obtain HMG-CoA reductase inhibitors of high purity, with high yields, lower production costs and suitable ecological balance.

专利号:US-7141602-B2
优先权日:1998-09-18
标题:Process for obtaining HMG-CoA reductase inhibitors of high purity
发明人：GRAHEK ROK; MILIVOJEVIC DUSAN; BASTARDA ANDREJ
权利人:LEK PHARMACEUTICALS
摘要:Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura, Micromonospora , some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-CoA reductase inhibitors using so-called displacement chromatography. Use of the invention enables one to obtain HMG-CoA reductase inhibitors of high purity, with high yields, lower production costs and suitable ecological balance.